Tiger Brokers

BUZZ-Cumberland jumps as heart drug for muscle‑wasting disease gets FDA's fast-track tag

Reuters
Feb 04
BUZZ-Cumberland jumps as heart drug for muscle‑wasting disease gets FDA's fast-track tag

** Shares of  drugmaker Cumberland Pharmaceuticals CPIX.O rise 15.04% to $4.36

**  Co says FDA granted fast track status to its experimental drug ifetroban for heart disease tied to Duchenne muscular dystrophy, a muscle‑wasting condition that weakens the heart

**  Co says ifetroban is an oral treatment and has orphan drug and rare pediatric disease tags

** A recent mid-stage study showed a 5.4% improvement in heart function after 12 months of treatment, co says

** U.S. FDA's "fast track" tag aims to speed development and review of drugs for serious conditions with unmet medical needs

** Duchenne muscular dystrophy affects boys and gradually damages muscles, including the heart, leading to life‑threatening complications

** Shares up ~68% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10